Cannabis Use Linked to Adverse Cardiovascular Outcomes
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Feb. 28, 2024 -- Cannabis use is associated with adverse cardiovascular outcomes, according to a study published online Feb. 28 in the Journal of the American Heart Association.
Abra M. Jeffers, Ph.D., from the University of California in San Francisco, and colleagues examined the association between cannabis use and cardiovascular outcomes via the population-based, cross-sectional study of 2016 to 2020 data from the Behavioral Risk Factor Surveillance Survey from 27 American states and two territories. In adults aged 18 to 74 years, the association of cannabis use with self-reported cardiovascular outcomes was examined in multivariable models, adjusting for tobacco use and other characteristics.
The researchers found that the prevalence of daily and nondaily cannabis use was 4 and 7.1 percent, respectively, among the 434,104 respondents. For the association of daily cannabis use and coronary heart disease, myocardial infarction, stroke, and the composite outcome, the adjusted odds ratios (95 percent confidence intervals) were 1.16 (0.98 to 1.38), 1.25 (1.07 to 1.46), 1.42 (1.20 to 1.68), and 1.28 (1.13 to 1.44), respectively; proportionately lower log odds were seen for days of use between zero and 30 per month. Daily cannabis use was also associated with myocardial infarction, stroke, and the composite outcome among never-tobacco smokers (adjusted odds ratios [95 percent confidence intervals], 1.49 [1.03 to 2.15], 2.16 [1.43 to 3.25], and 1.77 [1.31 to 2.40], respectively). For men younger than 55 years and women younger than 65 years, relationships between cannabis use and cardiovascular outcomes were similar.
"Patients and policymakers need to be informed of these potential risks, especially given the declining perception of risk associated with cannabis use," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted February 2024
Read this next
Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...
DNA Methylation-Based Epigenetic Age Mediates Link Between LE8 Score, CVD
WEDNESDAY, May 29, 2024 -- The associations between Life's Essential 8 (LE8) and cardiovascular health are mediated by DNA methylation-based epigenetic age, according to a study...
Semaglutide Boosts Kidney Outcomes With Obesity + Cardiovascular Disease
TUESDAY, May 28, 2024 -- Once-weekly subcutaneous semaglutide shows a benefit for kidney outcomes in people with overweight or obesity and established cardiovascular disease...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.